Trueblood Wealth Management LLC Purchases Shares of 2,703 Edwards Lifesciences Co. (NYSE:EW)

Trueblood Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences Co. (NYSE:EW) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 2,703 shares of the medical research company’s stock, valued at approximately $206,000.

Other institutional investors have also added to or reduced their stakes in the company. Advisors Asset Management Inc. lifted its stake in shares of Edwards Lifesciences by 0.3% in the 1st quarter. Advisors Asset Management Inc. now owns 43,556 shares of the medical research company’s stock valued at $5,127,000 after purchasing an additional 117 shares during the last quarter. Apollon Wealth Management LLC lifted its stake in shares of Edwards Lifesciences by 1.0% in the 1st quarter. Apollon Wealth Management LLC now owns 12,487 shares of the medical research company’s stock valued at $1,033,000 after purchasing an additional 119 shares during the last quarter. Geller Advisors LLC lifted its stake in shares of Edwards Lifesciences by 6.5% in the 1st quarter. Geller Advisors LLC now owns 1,965 shares of the medical research company’s stock valued at $231,000 after purchasing an additional 120 shares during the last quarter. Legacy Wealth Asset Management LLC lifted its stake in shares of Edwards Lifesciences by 0.8% in the 4th quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock valued at $1,293,000 after purchasing an additional 134 shares during the last quarter. Finally, KCM Investment Advisors LLC lifted its stake in shares of Edwards Lifesciences by 2.7% in the 1st quarter. KCM Investment Advisors LLC now owns 5,392 shares of the medical research company’s stock valued at $635,000 after purchasing an additional 142 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity

In other news, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction on Friday, January 5th. The stock was sold at an average price of $72.98, for a total value of $2,141,963.00. Following the transaction, the director now directly owns 4,486 shares in the company, valued at approximately $327,388.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the transaction, the chief financial officer now directly owns 19,248 shares in the company, valued at approximately $1,506,925.92. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Michael A. Mussallem sold 29,350 shares of the business’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $72.98, for a total value of $2,141,963.00. Following the transaction, the director now owns 4,486 shares in the company, valued at $327,388.28. The disclosure for this sale can be found here. In the last three months, insiders have sold 182,349 shares of company stock worth $15,334,555. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Trading Up 0.4 %

Shares of NYSE EW opened at $95.53 on Friday. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. The business has a fifty day simple moving average of $85.90 and a two-hundred day simple moving average of $75.99. The firm has a market cap of $57.44 billion, a PE ratio of 41.53, a price-to-earnings-growth ratio of 4.63 and a beta of 1.05. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.64. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.50 billion. During the same period in the previous year, the company posted $0.64 EPS. Edwards Lifesciences’s revenue was up 13.3% on a year-over-year basis. Analysts expect that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on EW shares. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. Truist Financial raised their price target on Edwards Lifesciences from $78.00 to $84.00 and gave the stock a “buy” rating in a research note on Friday, December 22nd. Citigroup lowered Edwards Lifesciences from a “buy” rating to a “neutral” rating in a research note on Monday, December 11th. Wells Fargo & Company raised Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price target for the company in a research note on Friday, February 2nd. Finally, Morgan Stanley raised their price target on Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research note on Thursday, March 21st. One research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $88.80.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.